NCT06329570 is a Phase 1, PHASE2 clinical trial of NaviFUS System in Glioblastoma Multiforme, sponsored by NaviFUS Corporation.

Who is sponsoring NCT06329570?

NCT06329570 is sponsored by NaviFUS Corporation.

What drugs are being tested in NCT06329570?

Interventions in NCT06329570: NaviFUS System, Lumason, Bevacizumab.

What condition does NCT06329570 study?

NCT06329570 studies Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor, Neoplasms, Neoplasms, Nerve Tissue.

Is NCT06329570 still recruiting?

NCT06329570 is currently recruiting now. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT06329570

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Recruiting now Phase 1, PHASE2 Last updated 9 April 2026

What this trial tests

Phase 1, PHASE2 trial testing NaviFUS System in Glioblastoma Multiforme in 10 participants. Currently enrolling.

Timeline

22 October 2024

Primary endpoint
31 December 2027

31 March 2028

Quick facts

Lead sponsor	NaviFUS Corporation
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	22 October 2024
Primary completion	31 December 2027
Estimated completion	31 March 2028
Sites	1 location across United States

Drugs / interventions tested

NaviFUS System
Lumason — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Glioblastoma — all drugs for Glioblastoma →
Glioma — all drugs for Glioma →
Brain Tumor — all drugs for Brain Tumor →

Sponsor

NaviFUS Corporation — full company profile →

Who can join

18 and older, any sex, with Glioblastoma Multiforme or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Angiogenesis in Glioblastoma-Treatment Approaches.
Nowacka A, Śniegocki M, Smuczyński W, Bożiłow D, et al · · 2025 · cited 20× · PMID 40136656 · DOI 10.3390/cells14060407
CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence.
Yaacoub S, Vannoy E, Maslova S, Haffey A, et al · · 2025 · cited 6× · PMID 40612954 · DOI 10.3389/fimmu.2025.1596499
Clinical Trials of Focused Ultrasound for Brain Tumors.
Lu VM, Niazi TN. · · 2025 · cited 3× · PMID 39941880 · DOI 10.3390/cancers17030513
MR Imaging-Guided Focused Ultrasound-Clinical Applications in Managing Malignant Gliomas.
Chen H, Anastasiadis P, Woodworth GF. · · 2024 · cited 3× · PMID 39322356 · DOI 10.1016/j.mric.2024.05.006
Ultrasound targeted microbubbles for theranostic applications in liver diseases: from molecular imaging to targeted therapy.
Zhang C, Zhang Q, Xu Q, Jiang X, et al · · 2025 · cited 2× · PMID 40771132 · DOI 10.1080/10717544.2025.2541656

Verify or expand the search:

Other trials of NaviFUS System

Trials testing the same drug.

NCT07274787 — Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma · NA · not yet recruiting
NCT06388707 — A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Dr · Phase 1, PHASE2 · recruiting
NCT05947656 — Evaluation of the NaviFUS System in Drug Resistant Epilepsy · NA · recruiting
NCT04999046 — NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy · NA · completed
NCT04988750 — Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients · NA · completed

Other recruiting trials for Glioblastoma Multiforme

Currently open trials in the same condition.

NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT06585527 — Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma · Phase 1 · recruiting

Other NaviFUS Corporation trials

Trials by the same sponsor.

NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT06388707 — A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Dr · Phase 1, PHASE2 · recruiting
NCT06492720 — A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Re · NA · recruiting
NCT04999046 — NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy · NA · completed
NCT04988750 — Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06329570 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NaviFUS Corporation
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06329570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing